Journal Scans
Indoleamine 2,3-Dioxygenase, a New Prognostic Marker in Sentinel Lymph Nodes of Melanoma Patients
Indoleamine 2,3-Dioxygenase As a Predictive Marker for Melanoma
R Speeckaert, K Vermaelen, N Autier, L Brochez, et al
20110925
2011 Oct 25
Eur J Cancer
Indoleamine 2,3-Dioxygenase, a New Prognostic Marker in Sentinel Lymph Nodes of Melanoma Patients
Eur J Cancer. 2011 Oct 25;[Epub Ahead of Print], R Speeckaert, K Vermaelen, N Autier, L Brochez, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Indoleamine 2,3-dioxygenase (IDO), an enzyme with immunosuppressive properties is considered as a factor that impairs the antitumour immune response in melanoma. In this study, we investigated the expression of IDO in sentinel nodes of melanoma patients to determine its prognostic relevance.Patients and Methods: One hundred and sixteen melanoma patients were enrolled in this study with a median follow-up time after diagnosis of 71 months. The expression of IDO and forkhead box P3 (Foxp3)...
